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The relationship between psoriasis and increased risk of cardiovascular disease (CVD) is controversial. We
critically evaluate 14 cohorts and meta-analyze the magnitude of CVD risk for the primary outcomes of CVD
mortality, stroke, and myocardial infarction (MI), and establish subgroup risk for different psoriasis severities and
age groups. Increased CVD risk was identified only in individuals with severe psoriasis (defined as requiring
systemic therapy or hospital admission): the risk ratio relative to the general population was 1.37 (95% confidence
interval (CI) 1.17–1.60) for CVD mortality, 3.04 (95% CI 0.65–14.35) for MI, and 1.59 (95% CI 1.34–1.89) for stroke. The
relative risks of CVD were highest in the younger, severe psoriasis population (e.g., 3.10 (95% CI 1.98–4.86) for MI
at 30 years), and absolute risks were greatest in older individuals with severe psoriasis (e.g., 23.2 excess MIs per
10,000 person-years at 60 years). Uncertainty remains about whether CVD risk is directly attributable to psoriasis,
as the majority of studies failed to adequately adjust for key traditional risk factors.
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INTRODUCTION
Psoriasis is one of the most common immune-mediated
inflammatory disorders, with prevalence estimates worldwide
ranging from 0  91% (USA) to 8  5% (Norway) (Parisi et al.,
2012). Extent varies from a few scaly plaques at extensor sites
to whole-body involvement, and for many individuals it
results in profound functional, psychological, and social
morbidity (Rapp et al., 1999). Some population-based cohort
studies also suggest that individuals with psoriasis (Mallbris
et al., 2004; Gelfand et al., 2006; Kurd et al., 2010), in
common with other inflammatory autoimmune diseases such
as rheumatoid arthritis (Wolfe et al., 2003; Maradit-Kremers
et al., 2005) and inflammatory bowel disease (Yarur et al.,
2011), are at an increased risk of cardiovascular disease
(CVD). These findings have led some investigators to
hypothesize, first, that the documented association between
psoriasis and CVD reflects a causal relationship (i.e., systemic
inflammation is driving CVD risk), and, second, that the use of
systemic treatment for psoriasis with methotrexate and
biological drugs will therefore reduce CVD risk (Reich,
2012). Such hypotheses remain to be proven, but there
are at least five trials registered to investigate the impact
of biological therapies on various surrogate markers of
cardiovascular health US National Institute of Health (http://
clinicaltrials.gov/, accessed 9 January 2013).
This reported association between psoriasis and CVD risk
has been rapidly incorporated into clinical practice, with
psoriasis cited as an independent risk factor for CVD in recent
European guidelines on CVD prevention (Fifth Joint Task
Force of the European Society of Cardiology, 2012). How-
ever, the prevalence of traditional risk factors for CVD,
including smoking, excess alcohol intake, hypertension,
hyperlipidemia, obesity, and insulin resistance (manifest
clinically as the metabolic syndrome), are also reported to
be higher in individuals with psoriasis (Naldi et al., 2005;
Sommer et al., 2006; Gisondi et al., 2007). These
comorbidities may account for some or all of the increased
CVD risk, and may be more important indicators of risk than
psoriasis. Furthermore, if future research does indicate
improvement in CVD risk with biological therapies,
understanding the size of CVD risk directly attributable to
psoriasis becomes important. We aimed to summarize the
evidence on the risk of CVD associated with psoriasis in
different populations and across different disease severities.
We pooled summary statistics of risk estimates, and identified
specific subgroups at particular risk. We also reviewed
the evidence for a causal relationship between psoriasis and
CVD. These data are key to informing clinical decision-
making and healthcare planning.
RESULTS
Study characteristics
Of the 14 included studies, 10 were population-based cohorts,
and sample sizes in the psoriasis group ranged from 462
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to 130,976. All but one of the studies reported European or
North American populations, with one (Lin et al., 2011) being
from Taiwan (Supplementary Table S1 online). The most
common limitations were retrospective analysis and inade-
quate adjustment for confounders, which varied between the
studies (Table 1).
Assessment of publication bias using formal measures of
funnel plot asymmetry was not possible, and the small number
of studies per subgroup meant that no conclusions could be
drawn from visual inspection.
Some studies stratified results for disease severity, but the
definitions of mild and severe psoriasis differed between studies.
Requirement for systemic treatments or hospital admission were
used as surrogate measures indicating severe disease, rather than
formal severity assessment scores. The diagnoses, of both
psoriasis and comorbidities, were assessed according to nation-
ally or internationally recognized classifications (e.g., ICD,
Oxford Medical Information Systems, and Read codes recorded
in medical records). Exceptions to this were the definition of
psoriasis being based on prescriptions for vitamin D analogs
(Ahlehoff, 2011), and both psoriasis and the outcomes being
defined according to self-report of a physician diagnosis,
although data limited to confirmed psoriasis cases according
to the self-administered Psoriasis Screening Tool were also
reported (Li et al., 2012). One cohort included only patients
treated with psoralen plus UVA for psoriasis in a clinical trial
setting, with the method of psoriasis diagnosis being unclear
(Stern et al., 1984; Stern and Huibregtse, 2011).
CVD mortality
Five studies estimated the incidence of CVD mortality in
individuals with psoriasis compared with individuals
without ((Figure 1a); (Boffetta et al., 2001; Mallbris et al.,
2004; Mehta et al., 2010; Ahlehoff et al., 2011a; Stern and
Huibregtse, 2011). For mild psoriasis, one study suggested
that psoriasis had a small protective effect (standardized
mortality ratio (SMR): 0.94 (95% confidence interval (CI)
0.89–0.99)) (Mallbris et al., 2004), and the other study
suggested that psoriasis was a small risk factor ((incidence
rate ratio: 1.14 (95% CI 1.06–1.22)); (Ahlehoff et al., 2011a))
with significant heterogeneity present. In severe psoriasis, four
studies (including one reporting a hazard ratio from
multivariable analysis) demonstrated a large statistically
significant relative increase in the incidence of CVD
mortality (Boffetta et al., 2001; Mallbris et al., 2004; Mehta
et al., 2010; Ahlehoff et al., 2011a), whereas one study
suggested that there may be no difference (Stern and
Huibregtse, 2011). The pooled SMR from four studies was
1.37 (95% CI 1.17–1.60), which was significantly different
from the findings in the mild subgroup (P¼0  02). The
absolute increase in incidence in individuals with severe
psoriasis was 1 in 283 patients per year (or a 3  5% excess
10-year risk); (Mehta et al., 2010).
Consistent with the increased risk of ‘all cause’ CVD
mortality, there was an increased incidence of death due to
specific cardiovascular events in individuals with severe psori-
asis. Cerebrovascular disease mortality (SMRs: 1.33 (95% CI
1.11–1.59) and 1.63 (95% CI 1.47–1.80)) and arterial disease
mortality (SMR: 1.34 (95% CI 0.97–1.80)) demonstrated a
similar magnitude of risk to overall CVD mortality (Boffetta
et al., 2001; Mallbris et al., 2004). A greater risk was reported
for ischemic heart disease mortality (SMR: 1.86 (95% CI 1.76–
1.96)) (Mallbris et al., 2004). These outcomes were not
reported for mild psoriasis.
Table 1. Adequacy of controlling for potential confounders that may contribute to CVD risk
Study Age Sex Smoking Alcohol excess BMI or obesity Hyperlipidemia Hypertension Diabetes Calendar time
(Ahlehoff et al., 2011a)* | | B B | |
(Ahlehoff et al., 2011b)* | | B B | |
(Ahlehoff et al., 2011c)* | | B B | |
(Boffetta et al., 2001) | | |
(Brauchli et al., 2009)* | | |
(Gelfand et al., 2006) | | | / | | | |
(Gelfand et al., 2009) | | | / | | | |
(Kaye et al., 2008) | | |
(Li et al., 2012)* | | | | | | | |
(Lin et al., 2011)* | | | | | |
(Mallbris et al., 2004)* | | |
(Mehta et al., 2010) | | | / | | | |
(Stern and Huibregtse, 2011) | | |
(Wakkee et al., 2010) | | | | | |
Abbreviations: BMI, body mass index; CVD, cardiovascular disease.
|Controlled for.
BAdjusted for surrogate markers.
/Adjusted in sensitivity analyses.
*Excluded those with outcome of interest at study entry.
EJ Samarasekera et al.
Incidence of Cardiovascular Disease in Psoriasis
www.jidonline.org 2341
Myocardial infarction
Seven studies reported the incidence of myocardial infarction
(MI) (Figure 1b), and no other coronary heart disease out-
comes were reported. Five studies included all psoriasis
severities (Kaye et al., 2008; Brauchli et al., 2009; Wakkee
et al., 2010; Lin et al., 2011; Li et al., 2012). Four of these
studies reported an increased incidence of MI, whereas one
study suggested no effect of psoriasis (hazard ratio: 0.94 (95%
CI 0.80–1.11)) (Wakkee et al., 2010). The pooled estimate
from four independent cohorts (excluding the Brauchli study,
which reported an overlapping cohort with Kaye et al.) was
1.40 (95% CI 1.03–1.89); this should be interpreted with
caution, owing to the high heterogeneity between studies
(I2¼ 86%).
Two other studies (Gelfand et al., 2006; Ahlehoff et al.,
2011a) reported relative incidence rates for mild and severe
psoriasis separately. Both studies reported a statistically
significant increased incidence of MI for mild and severe
psoriasis, but the magnitude of the increase was greater in
severe psoriasis (pooled estimate 3.40 (95% CI 0.65–14.35)
based on individual study estimates of 1.45 (1.10–1.91) and
7.08 (3.06–16.37)) than in mild psoriasis (pooled estimate
1.34 (95% CI 1.07–1.68) based on individual study estimates
of 1.22 (1.12–1.33) and 1.54 (1.24–1.91)). However, the
difference between severity subgroups based on the pooled
data was not statistically significant (P¼ 0.31).
The absolute increased MI incidence in individuals with
psoriasis was reported as 1 in 2,174 individuals per year
(0  46% increase in 10-year risk) and 1 in 645 individuals per
year (1  55% increase in 10-year risk) for mild and severe
psoriasis, respectively (Gelfand et al., 2006).
The risk of all-cause mortality was not significantly different
in individuals with psoriasis compared with the general
population following first-time MI (hazard ratio: 1.18 (95%
CI 0.97–1.43)); (Ahlehoff et al., 2011c).
Stroke
Five studies reported the incidence of stroke (Figure 1c); (Kaye
et al., 2008; Brauchli et al., 2009; Gelfand et al., 2009;
Ahlehoff et al., 2011b; Li et al., 2012). Three studies included
all psoriasis severities (Kaye et al., 2008; Brauchli et al., 2009;
Li et al., 2012). Each study individually showed no statistically
significant difference between those with and without psori-
asis; however, the pooled estimate from two independent
cohorts (Brauchli study excluded as above) showed psoriasis
to be a weak risk factor ((1.13 (95% CI 1.01–1.26)); (Kaye
et al., 2008; Li et al., 2012)).
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Figure 1. Incidence estimates for cardiovascular disease outcomes in
individuals with psoriasis compared with those without. (a) Cardiovascular
disease (CVD) mortality; (b) myocardial infarction; (c) stroke. *Defined as
vitamin D analog prescription claims without hospitalizations (Ahlehoff et al.,
2011a), outpatients treated at dermatological wards with psoriasis as the main
diagnosis (Mallbris et al., 2004), and psoriasis diagnosis but no history of
systemic therapy (Gelfand et al., 2006; Gelfand et al., 2009). wDefined as
hospitalizations (including outpatient visits) for psoriasis or psoriatic arthritis
(Ahlehoff et al., 2011a), inpatients treated at dermatological wards with
psoriasis as the main diagnosis (Mallbris et al., 2004; Boffetta et al., 2001),
systemic therapy consistent with severe disease (Mehta et al., 2010), and
psoriasis diagnosis plus a history of systemic therapy (Gelfand et al., 2006;
Gelfand et al., 2009); the definition was unclear in one study, although most
had received previous systemic therapy and the mean BSA coverage was 33%
(Stern and Huibregtse, 2011). CI, confidence interval; HR, hazard ratio; IRR,
incidence rate ratio; IV, inverse variance; SMR, standardized mortality ratio.
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As with MI, the increase was greater for the severe group:
1.59 (95% CI 1.34–1.89) compared with 1.15 (95% CI
0.98–1.35) in the mild group based on a pooled estimate from
two studies (Gelfand et al., 2009; Ahlehoff et al., 2011b). The
difference between severity subgroups was statistically
significant (P¼0.006).
The absolute increased incidence of stroke in individuals
with psoriasis was estimated as 1 in 4,115 individuals per year
(0.24% increase in 10-year risk) and 1 in 530 individuals per
year (1.89% increase in 10-year risk) for mild and severe
psoriasis, respectively (Gelfand et al., 2009).
Increased risk was also reported for atherosclerosis, angina,
peripheral vascular disease, and atrial fibrillation across all
severities but not for ischemic heart disease (Kaye et al., 2008;
Wakkee et al., 2010; Ahlehoff et al., 2011b); (Supplementary
Table S2 online).
CVD risk modification by age
Four studies reported the relative risk of incident CVD at
different ages for individuals with psoriasis compared with
those without (Mallbris et al., 2004; Gelfand et al., 2006;
Ahlehoff et al., 2011a, 2011b). The studies reported different
outcomes: atrial fibrillation, stroke, MI, ischemic heart disease
mortality, cerebrovascular disease mortality, and overall CVD
mortality.
For severe psoriasis, the relative increase in CVD incidence
was generally greater in younger groups for CVD mortality,
MI, stroke, and atrial fibrillation outcomes (Supplementary
Table S3 online). However, the large relative increase in
incidence among younger individuals equates to a low
absolute incidence rate; for MI, in the youngest age group, a
relative increase of 3.1 refers to an increased risk of 1 in 1,389
individuals per year in the severe psoriasis group. This is a
lower absolute incidence of MI than that among the older age
group (1 in 429 individuals per year), although the relative
incidence was only 1  36 times higher (Gelfand et al., 2006).
This study also reported that there was a significant interaction
between MI incidence and age variables in the analysis
(Gelfand et al., 2006).
No consistent pattern of age-related incidence was seen
for the mild and mixed psoriasis severity subgroups
(Supplementary Table S4 online).
DISCUSSION
Main findings
Our study shows that individuals with psoriasis requiring
systemic therapy or hospital admission (severe disease) have
a marked increase in the incidence of MI, stroke, and all-cause
CVD mortality, including cerebrovascular, ischemic, and
arterial disease mortality. However, the risk of CVD in cohorts
not stratified for disease severity is modest, and data in cohorts
with mild disease are inconsistent, with no effect or very small
relative risks across all outcomes. Taken together, these data
indicate a clinically relevant increase in CVD risk only in
individuals with severe disease. We show that the relative risks
are greatest in younger populations, whereas in absolute terms
the number of CVD events attributable to psoriasis per year is
modest across all disease severities and particularly low for
young individuals and those with mild psoriasis. We also
address the question of whether the reported CVD risk is
directly attributable to psoriasis by limiting our analysis to data
reporting incident CVD. However, confidence in the accuracy
of the effect estimates is limited by incomplete controlling for
important confounding factors in most studies, particularly
traditional risk factors for CVD, and the CVD risk that is
directly attributable to psoriasis remains unclear. Nevertheless,
when considering only those studies that performed multi-
variable analysis of time-to-event data, the most appropriate
type of analysis, there was consistent evidence across all
primary outcomes, indicating that the incidence is signifi-
cantly higher in severe psoriasis patients than in individuals
without psoriasis (Gelfand et al., 2006, 2009; Mehta et al.,
2010). The within-study differences between mild and severe
psoriasis in the Gelfand cohorts were also significant
(P¼ 0.0006 for MI and P¼0.03 for stroke).
Study heterogeneity
Heterogeneity was noted for all outcomes. For CVD mortality
in severe psoriasis, in contrast to consistent findings among
four other studies, one cohort of psoralen plus UVA-treated
patients (Stern and Huibregtse, 2011) showed no increase in
CVD mortality compared with a matched general population
cohort. The cohort represented a selected population
comprising individuals who were recruited to a clinical trial,
all having psoralen plus UVA exposure; thus, the findings may
not be wholly generalizable. In addition, their definition of
severe psoriasis differed from other studies; each center had to
enter 50 or more patients with at least 30% BSA coverage, but
subsequent patients could be enrolled with o30% coverage
(the mean BSA was 33%). Of note, four out of five studies
(including Stern and Huibregtse (2011)) only calculated a
standard mortality ratio, rather than a multivariable analysis
controlling for relevant confounders. All of these factors
could be relevant when considering the difference in
findings (see also Gelfand et al. (2013)). Interestingly, the
subanalysis within the Stern cohort also supports the increased
risk of CVD mortality in more severe disease, as multivariable
analysis showed a trend toward increased risk in more
extensive psoriasis even when the referent is moderate
psoriasis (443% vs. o15% BSA; Supplementary Figure S1
online).
For MI and stroke, among the studies reporting all psoriasis
severities, one study (Li et al., 2012) reporting a female nurse
population showed higher relative incidence rates of MI and
stroke in the psoriasis group compared with other studies. The
reason for this is unclear. Another study (Lin et al., 2011) also
reported a higher relative incidence of MI, possibly because
the study population consisted of those accessing ambulatory
care, who are more likely to have severe disease. In studies
reporting data for mild and severe psoriasis subgroups,
heterogeneity may be driven by the effect of age on relative
risk, as the effect estimates from the Gelfand study (Gelfand
et al., 2006) differed by age. In support of this, risk estimates
from age-stratified data showed consistent findings between
two studies (Gelfand et al., 2006; Ahlehoff et al., 2011a)
within the younger and older groups, with higher risk in the
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younger group in both mild and severe psoriasis
(Supplementary Figure S2 online).
For each outcome, there was inconsistency in the mild
psoriasis subgroup results, where the association is weak and
thus susceptible to variations in baseline characteristics and
study design. There was also variability in the definition of
mild psoriasis, including the use of vitamin D analogs but not
systemic psoriasis therapies in one study (Ahlehoff et al.,
2011a), no use of systemic therapies (Gelfand et al., 2006),
and psoriasis treated in an outpatient setting (Mallbris et al.,
2004).
Study strengths and limitations
A key strength of our study is limiting the analysis to studies
investigating incident (as opposed to prevalent) CVD. In
addition, a comprehensive and transparent literature search
identified all relevant reports, and the methodological quality
of included studies was assessed according to standard and
detailed criteria.
However, we acknowledge important limitations. Our
systematic review is limited by the quality of the included
studies: first, the majority involved retrospective data analyses,
which increase the risk of bias associated with the recording of
baseline data, the need for imputation, and potential selection
bias. Notably, very few of the studies reported how missing
data were handled or if imputation was used. High risk of
selection bias was noted in three studies (Boffetta et al., 2001;
Mallbris et al., 2004; Stern and Huibregtse, 2011), as the
exposed and unexposed group were sampled from different
cohorts.
Second, there was incomplete correction for relevant con-
founders in most of the studies. This is important when
considering whether there is a causal relationship between
CVD risk and psoriasis in the context of a population in which
the incidence of traditional risk factors for CVD such as
diabetes, hypertension (Qureshi et al., 2009), and smoking
(Poikolainen et al., 1999) are increased. This problem was
addressed partly by some investigators undertaking multiple
sensitivity analyses to explore the robustness of results to
changes in the analyses and assumptions. For example, the
estimated magnitude of unmeasured confounders that could
nullify the results for ischemic stroke, assuming a prevalence
of 20%, would have to be greater than the effects and
distribution of any of the measured confounders (valvular
heart disease or prior MI); (Ahlehoff et al., 2011b). Two study
groups (Gelfand et al., 2006, 2009; Mehta et al., 2010) also
showed that the association between psoriasis and
cardiovascular death held true when excluding those with
psoriatic arthritis or those who had received methotrexate or
ciclosporin.
Third, psoriasis was ascribed as ‘‘severe’’ in most of the
studies if systemic treatments were used, which may have
resulted in misclassification bias. Therefore, an alternative
explanation for findings in the severe cohort is that the treat-
ments themselves drive the risk (for example, ciclosporin and
acitretin cause hyperlipidemia).
Fourth, there is a risk of detection bias, with a possible
alternative explanation for the increased CVD incidence
recorded in psoriasis being that individuals with psoriasis are
more likely to seek medical attention and thus be screened for
CVD; thus, the recorded increased incidence may be an
artifact of more complete detection rather than psoriasis itself
driving the effect.
Fifth, in relation to our analysis, we note the inherent
limitations of meta-analysis of observational data, particularly
in light of the noted study variability and the small number of
studies available for the severity subgroups, which poses a
challenge for clear interpretation. In addition, pooling of the
heterogenous results for MI in severe psoriasis in a random-
effects model produced a nonsignificant result, although both
individual studies demonstrated severe psoriasis to be a risk
factor. Finally, with regard to the age subgroups, we note the
risk of chance effects owing to splitting the data set according
to two different parameters (severity and age).
Findings compared with other studies
Our findings are consistent with those in three cross-sectional
studies showing elevated prevalence of various CVD end
points in psoriasis (Cohen et al., 2007; Prodanovich et al.,
2009; Xiao et al., 2009), and with elevated estimated risks of
coronary heart disease and stroke based on baseline
demographic data from phase II and III psoriasis intervention
studies (Kimball et al., 2010). One other systematic review has
also reported an increased relative risk of the composite
vascular end point of MI and stroke in psoriasis (Xu and
Zhang, 2012).
In rheumatoid arthritis (Avina-Zubieta et al., 2008; Meune
et al., 2009), pooled estimates of relative risk are virtually
identical to those reported in our study, and, notably,
ascertainment of specific disease-associated risk is similarly
complicated by confounders, where a similar spectrum of risk
factors occurs (Boyer et al., 2011). In addition, one study
(Ahlehoff et al., 2011a) showed that, based on the Danish
patient register, the increase in CVD mortality risk associated
with severe psoriasis was comparable to that associated with
diabetes (incidence rate ratio 1.57 (1.27–1.94) for severe
psoriasis and 1.59 (1.56–1.63) for diabetes; P¼0.72).
Study implications
Our findings indicate that the risks of CVD are largely
confined to severe disease and, specifically, to individuals
requiring systemic therapy or hospital admission. Although
there is a paucity of accurate epidemiological data about
psoriasis, individuals with severe disease constitute a minority:
in one US-based study, the proportion of individuals with
body surface area involvement410% (an accepted definition
of severe) was 5  25%. In the Gelfand and Ahlehoff cohorts,
the rates of ‘‘severe’’ psoriasis (variably defined) were
2.2–2.9% and 7.1%, respectively. Therefore, the diagnosis
of psoriasis alone, without consideration of disease severity, is
unlikely to be a clinically useful marker of CVD risk, and
recommendations for formal cardiovascular risk assessment
should be limited to individuals with severe disease, whereas
proactive management of cardiovascular risk factors in indi-
viduals with psoriasis, as in the general population, is also
important. There is some evidence to indicate that there may
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be a causal link between severe psoriasis and CVD risk;
however, given the serious methodological shortcomings in
some of the studies in relation to correction for traditional risk
factors, there is uncertainty about the size of CVD risk directly
attributable to psoriasis. Choice of treatment strategies should
therefore remain driven by skin disease severity rather than by
any purported benefit to cardiovascular risk profile.
CONCLUSIONS
Severe psoriasis is associated with an increased risk of CVD.
Research is required to better understand the complex rela-
tionship between psoriasis, traditional risk factors, and CVD.
Long-term, large-scale cohort studies that adequately control
for confounding factors and detection bias are required to
address the question of whether aggressive treatment of severe
psoriasis has an impact on clinically relevant CVD end points.
MATERIALS AND METHODS
Search strategy
A systematic literature search of MEDLINE, Embase, Cinahl, and The
Cochrane Library was conducted (Supplementary Table S5 online).
A total of 4,646 abstracts were retrieved, 118 ordered, and 15
included in the review (Supplementary Figure S2 online). The
definition of CVD was based on the World Health Organization
classification (Mendis et al., 2011). Systematic reviews or cohort
studies of the incidence of CVD reporting the presence of psoriasis as
a prognostic factor were included. The primary outcomes were CVD
mortality, MI, and stroke. Prognostic factors that allowed subgroups of
the psoriasis population to be investigated were prespecified as
disease severity and age.
Case–control or cross-sectional studies were excluded, as were
papers lacking full reports.
Data extraction and quality assessment
The studies were all large cohorts (Supplementary Table S1 online).
Methodological quality was assessed according to the risk of bias
across five domains based on established criteria (Hayden et al.,
2006); (Supplementary Table S6 online). This included adjustment
for key confounding factors (age, sex, smoking status, alcohol intake,
body mass index or obesity, hyperlipidemia, hypertension, and
diabetes) (Table 1). The other domains were attrition, prognostic
factor, and outcome biases.
Where possible, data for both minimally and maximally adjusted
risk estimates were extracted, although maximally adjusted risk
estimates are reported. Where more than one study reported on the
same or largely overlapping cohorts for the same outcome, the study
with the greatest number of person-years of follow-up was used. If this
was not distinguishable, the study using the most appropriate analysis
was used.
Statistical analysis
The relative risk estimates were combined using a random-effects
(DerSimonian and Laird) meta-analysis to provide a conservative
estimate of the effect owing to potential population differences
between the studies. The log of the risk estimate and its standard
error were calculated from the estimate, and its 95% CI was reported
in the studies, and these data were used to input into Review Manager
5.1 (Cochrane Collaboration, Copenhagen, Denmark). A value of
Pr0.05 was considered to be statistically significant. Data were
stratified a priori according to psoriasis disease severity, with the risk
for mild and severe psoriasis being presented separately when
possible. Heterogeneity was assessed by the w2 test for significance
at Po0.1 or an I2 inconsistency statistic of 450% to indicate
significant heterogeneity. Assessments of potential differences in
effect between subgroups were based on the w2 test for heterogeneity
statistics between subgroups.
We planned to assess publication bias using formal tests for funnel
plot asymmetry.
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